<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013284</url>
  </required_header>
  <id_info>
    <org_study_id>13-007084</org_study_id>
    <nct_id>NCT02013284</nct_id>
  </id_info>
  <brief_title>Is Our Microbiome a Predictor of Cardiac Risk</brief_title>
  <official_title>Is Our Microbiome a Predictor of Cardiac Risk?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine a relationship between a person's flora/bacteria in&#xD;
      their gut (the intestinal microbiome) and their risk of cardiovascular disease. Investigators&#xD;
      will look at inflammatory markers in the blood and also look at the genome of the bacteria in&#xD;
      the gut.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will look at inflammatory markers in the blood and also look at the genome of&#xD;
      the bacteria in the gut. This research is being done because Investigators believe that there&#xD;
      is a connection between the way food is digested by a person's gut bacteria and the&#xD;
      development of atherosclerosis (hardening of the arteries) and cardiovascular disease. The&#xD;
      ultimate goal of this research is to eventually determine if changes to the gut bacteria can&#xD;
      prevent cardiovascular disease or disease progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>50 cc blood obtained during angiogram and used for Endothelial Progenitor Cells analysis using antibodies for inflammatory markers. Plasma collection will be done for antibody analysis. Buffy coats will be frozen and stored for future genetic analysis.</measure>
    <time_frame>Blood samples will be obtained during the diagnostic angiogram.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stool samples will be collected to compare the fecal microbiota of patients with mild, moderate and severe coronary artery disease.</measure>
    <time_frame>Two weeks after the angiogram</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood (50 cc) and stool samples will be collected on consenting participants. Participants&#xD;
      will have the option of allowing us to store samples for future research&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consenting participants who are undergoing coronary angiography.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Anyone undergoing cardiac catheterization for suspected coronary artery disease over age&#xD;
        18.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients currently on long-term antibiotics who cannot stop them for at least 2 weeks&#xD;
             prior to providing a stool sample.&#xD;
&#xD;
          2. Patients on chronic laxatives who cannot stop for at least 2 weeks prior to stool&#xD;
             collection.&#xD;
&#xD;
          3. Patients on probiotics and cannot stop for 2 weeks prior to giving a stool sample&#xD;
             (yogurt is ok).&#xD;
&#xD;
          4. Patients who are unable to provide a stool sample to Mayo Clinic utilizing Fed Ex&#xD;
             overnight mail.&#xD;
&#xD;
          5. Patients who have had previous Coronary Artery Bypass Grafting procedure&#xD;
&#xD;
          6. Patients who have a colostomy&#xD;
&#xD;
          7. Transplant Patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir Lerman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amir Lerman, MD</last_name>
    <phone>507-255-4152</phone>
    <email>lerman.amir@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacob Bjerk</last_name>
    <phone>507-422-0467</phone>
    <email>Bjerk.jacob@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Albers, CRC</last_name>
      <phone>507-255-6884</phone>
      <email>albers.diana2@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Amir Lerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 11, 2013</study_first_submitted>
  <study_first_submitted_qc>December 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2013</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Amir Lerman</investigator_full_name>
    <investigator_title>Amir Lerman, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

